This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Conceptus 1Q Loss Widens On Revenue Dip

MOUNTAIN VIEW, Calif. (AP) â¿¿ Conceptus Inc., which develops the Essure permanent birth control procedure, said Tuesday that its first-quarter loss widened on a decline in revenue.

The results sent share plummeting in after-hours trading.

Conceptus lost $2.9 million, or 9 cents per share, compared with a loss of $2.4 million, or 8 cents per share, during the same period a year prior. Revenue fell 21 percent to $21.4 million from $27 million.

Analysts surveyed by FactSet expected a loss of 5 cents per share on $32.4 million in revenue.

The company said the unemployment situation and the loss of insurance coverage by some people partly affected the ability of consumers to pay for Essure.

"Macroeconomic pressures, challenging insurance trends, competitive trialing and our planned strategic focus were the primary factors that impacted our sales this quarter," said President and CEO Mark Sieczkarek, in a statement.

Looking ahead, the company expects sales between $135 million and $150 million in 2011. Analysts expect $142.6 million in sales.

Shares of Conceptus fell $2.09, or 13.9 percent, to $13 in after-hours trading, after gaining 18 cents to close at $15.09 during the regular trading session.
Copyright 2011 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
TSLA $149.01 0.69%
YHOO $26.88 -0.63%
AAPL $94.74 -0.28%
FB $100.46 0.71%
GOOG $687.27 0.66%


Chart of I:DJI
DOW 15,948.39 -78.66 -0.49%
S&P 500 1,848.65 -4.79 -0.26%
NASDAQ 4,274.7890 -8.9640 -0.21%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs